Latest Oncotype DX Stories
10% Test Volume Increase; 2% Product Revenue Increase, 3% Product Revenue Increase in Constant Currency REDWOOD CITY, Calif., May 5, 2015 /PRNewswire/ -- Genomic Health, Inc.
Use of Test Significantly Impacts Treatment Recommendations for One in Four Men and Improves Confidence in 85 Percent of Physicians REDWOOD CITY, Calif., April 30, 2015 /PRNewswire/
REDWOOD CITY, Calif., April 28, 2015 /PRNewswire/ -- Genomic Health, Inc.
11 Presentations at St.
Agreement Marks Important Milestone in Delivering Personalized Medicine to More Breast Cancer Patients Worldwide REDWOOD CITY, Calif., Feb.
A new study published in The Oncologist details a novel approach to identifying patients with stage II colorectal cancer who are most likely to benefit from additional treatment due to a high
REDWOOD CITY, Calif., Feb. 3, 2015 /PRNewswire/ -- Genomic Health, Inc.
- Plans to Secure CE Mark for a European Launch of the Non-Invasive Test and Submit a Pre-IDE to the U.S. FDA in 2015 - TEL-AVIV, Israel, Feb.
REDWOOD CITY, Calif., Jan. 5, 2015 /PRNewswire/ -- Genomic Health, Inc.
Positive Results of Largest Genomic Study in DCIS Reconfirm Oncotype DX is a Strong, Independent Predictor of Local Recurrence SAN ANTONIO, Dec.
- The horn of a unicorn considered as a medical or pharmacological ingredient.
- A winged horse with a single horn on its head; a winged unicorn.